Logo image
Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment
Journal article   Peer reviewed

Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment

Paul Nyirjesy and Jane R. Schwebke
Future microbiology, v 13(5), pp 507-524
01 Apr 2018
PMID: 29327947

Abstract

Life Sciences & Biomedicine Microbiology Science & Technology
Secnidazole is a next-generation 5-nitroimidazole approved for more than three decades in Europe, Asia, South America and Africa and recently in the USA as a single-dose (2 g) treatment of bacterial vaginosis (BV). Secnidazole is characterized by potent in vitro antimicrobial activity against BV-associated pathogens, as well as prolonged terminal elimination half-life and systemic exposure. These characteristics form the basis of effective and safe treatment of BV with a 2-g single-dose secnidazole regimen, which was recently confirmed in double-blind, placebo-controlled clinical trials conducted in the USA. The option to treat BV with single-dose secnidazole not only cures the primary infection but also may diminish risks of serious sequelae of untreated or undertreated infection.

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Microbiology
Logo image